感染

订阅

MedSci主页 / 所有栏目 / 感染

Lancet：有关埃博拉病人的随机对照试验的争议

2014-10-14 佚名 生物谷

埃博拉随机对照试验
关注

2014年10月10日 讯 /生物谷BIOON/ --近日，卫生专家敦促选出一种备用方案用来快速评价出新的埃博拉治疗方法的优劣。在写给《柳叶刀》杂志的资料中显示，来自非洲，欧洲，和美国的17个高级卫生专业人员和医学伦理学家，认为尽管随机对照试验(RCTs)在大多数情况下提供坚实有力的证据，但是针对埃博拉仍缺乏有效的治疗方案。如当前的常规治疗后的高死亡率，在受影响的地区缺乏有效的卫生保健系统意味

2014年10月10日 讯 /生物谷BIOON/ --近日，卫生专家敦促选出一种备用方案用来快速评价出新的埃博拉治疗方法的优劣。在写给《柳叶刀》杂志的资料中显示，来自非洲，欧洲，和美国的17个高级卫生专业人员和医学伦理学家，认为尽管随机对照试验(RCTs)在大多数情况下提供坚实有力的证据，但是针对埃博拉仍缺乏有效的治疗方案。如当前的常规治疗后的高死亡率，在受影响的地区缺乏有效的卫生保健系统意味着备择试验设计需要再考虑。

他们写道，“没有人坚持认同西方医疗工作者提供的zMapp方法和其他只是为了得到药物或常规治疗加安慰剂的随机调查研究。没有人在这种情况下会同意随机实验。在预后不良癌症中没有很好的治疗方法，没有实验对照组的研究证明可以被接受进行充分的部署，甚至在全面分析后科得到监管部门的许可。没有必要为了规则而不能直走捷径：必要的程序已经存在，并且已经在使用。”

“在普通情况下我们接受随机对照试验因为它能产生强有力的证据，但这种情况不适合处于历史上最严重的埃博拉病毒疫情中”他们总结道。“我们迫切需要能够提供生存机会的新的临床实验药物，因此，如果有该种药物的话应由世卫组织推荐使用从而来拯救生命。我们有创新项目但需要试验设计来证明它的实用性。我们应该使用这些创新性药物，而不是固执地坚持黄金标准用来开发不同的设置和目的。”

原始出处：

Clement Adebamowo a, Oumou Bah-Sow b, Fred Binka c, Roberto Bruzzone d, Arthur Caplan e, Jean-François Delfraissy f, David Heymann g, Peter Horby h, Pontiano Kaleebu i, Jean-Jacques Muyembe Tamfum j, Piero Olliaro k lEmail Address, Peter Piot m, Abdul Tejan-Cole n, Oyewale Tomori o, Aissatou Toure p, Els Torreele q, John Whitehead r.Randomised controlled trials for Ebola: practical and ethical issues.The Lancet, Early Online Publication, 13 October 2014.doi:10.1016/S0140-6736(14)61734-7


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827887, encodeId=1264182e887d3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 18 20:15:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650304, encodeId=136a16503046c, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Mar 16 11:15:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775278, encodeId=d5361e7527856, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 12 09:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987162, encodeId=3334198e1621c, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue May 26 19:15:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296152, encodeId=8694129615249, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Thu Oct 16 00:15:00 CST 2014, time=2014-10-16, status=1, ipAttribution=)]
    2015-08-18 howi

    #Lancet#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1827887, encodeId=1264182e887d3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 18 20:15:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650304, encodeId=136a16503046c, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Mar 16 11:15:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775278, encodeId=d5361e7527856, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 12 09:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987162, encodeId=3334198e1621c, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue May 26 19:15:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296152, encodeId=8694129615249, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Thu Oct 16 00:15:00 CST 2014, time=2014-10-16, status=1, ipAttribution=)]
    2015-03-16 tcm107hq

    #埃博拉病#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1827887, encodeId=1264182e887d3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 18 20:15:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650304, encodeId=136a16503046c, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Mar 16 11:15:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775278, encodeId=d5361e7527856, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 12 09:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987162, encodeId=3334198e1621c, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue May 26 19:15:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296152, encodeId=8694129615249, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Thu Oct 16 00:15:00 CST 2014, time=2014-10-16, status=1, ipAttribution=)]
    2015-01-12 amyloid

    #对照#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1827887, encodeId=1264182e887d3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 18 20:15:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650304, encodeId=136a16503046c, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Mar 16 11:15:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775278, encodeId=d5361e7527856, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 12 09:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987162, encodeId=3334198e1621c, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue May 26 19:15:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296152, encodeId=8694129615249, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Thu Oct 16 00:15:00 CST 2014, time=2014-10-16, status=1, ipAttribution=)]
    2015-05-26 般若傻瓜

    #对照试验#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1827887, encodeId=1264182e887d3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 18 20:15:00 CST 2015, time=2015-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650304, encodeId=136a16503046c, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Mon Mar 16 11:15:00 CST 2015, time=2015-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775278, encodeId=d5361e7527856, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jan 12 09:15:00 CST 2015, time=2015-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987162, encodeId=3334198e1621c, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue May 26 19:15:00 CST 2015, time=2015-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296152, encodeId=8694129615249, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Thu Oct 16 00:15:00 CST 2014, time=2014-10-16, status=1, ipAttribution=)]
    2014-10-16 lisa438

    #随机对照试验#

    0

相关资讯

狗真的会传播埃博拉吗？

埃博拉病毒存在于各种动物中，从蝙蝠到鸟类，从猪到豪猪。然而患上埃博拉疾病，和在个体之间或跨物种传播病毒是两码事，而这正是之前西班牙卫生部的一项举措会产生争议的原因——他们从法庭得到指令，在当地时间10月8日对一位在马德里感染埃博拉病毒的护士的狗实施了安乐死，声称有科学证据表明，狗可以将病毒传给人类。但是我们对哪些动物能够染上并传播这个致命病毒，又了解多少呢？美国疾控中心的主任汤姆·弗里登（Tom

美国本土首例埃博拉患者在医院死亡

据央视国际报道，美国本土确诊的首例埃博拉病毒携带者邓肯，于8日早晨，在美国得克萨斯州达拉斯一家医院死亡。利比里亚人邓肯，于9月中旬抵达得克萨斯州探亲，是美国第一个被确诊患有埃博拉的患者，住院期间不仅接受过常规治疗，也尝试试验性药物治疗，但最终还是没能挽救他的生命，也成为美国死于该疾病的第一人。

世卫组织公布埃博拉疫情新报告

图片来源：LOREDANA SIANI/OKAIROS 在世卫组织（WHO）公布西非埃博拉疫情发生6个月后，WHO近日再次公布了一项新的研究报告，报告警示埃博拉疫情正在快速恶化，甚至可能成为“西非人群中从未被预期到的一场大规模瘟疫”。 位于美国亚特兰大市的国家疾控中心（CDC）同时发布了一项关于这一致命病毒蔓延的新模型，其演示分析估计，最坏的情况是到2015年1月，超过14

Chimerix着手开展利用brincidofovir治疗埃博拉病毒研究

今年三月份，生物技术公司Chimerix公司因为一名极度虚弱的儿童而置身于全美媒体的风暴中心。然而迫于FDA关于新药的相关规定，Chimerix公司始终拒绝使用公司未进入临床研究阶段的药物治疗该儿童。此事一经国外媒体披露，立刻引发了社会大众关于医药伦理问题的讨论。随后，Chimerix公司被迫宣布将进行一项先行试验研究公司开发的特效药物brincidofovir治疗新病毒感染的研究。

美国埃博拉感染者已达12人，但特效药物ZMapp已用完

一名从利比里亚前往美国德克萨斯州达拉斯旅游的男子最近被确诊感染了埃博拉，这是美国本土出现的首例埃博拉患者。目前，该患者病情危重，已被隔离治疗。当地还有一人也出现了疑似埃博拉症状，并被隔离观察。据悉，美国本土第一名埃博拉患者虽病情非常危重，但神志清醒，知道索要食物。在抵达美国前，此人曾在布鲁塞尔专机。目前，第二例出现埃博拉症状的患者病情“严重”。美方正在密切监控与患者有密切接触的人员，其中包括5名儿

13名埃博拉患者服抗艾药拉米夫定获救

美国有线电视新闻网9月27日报道，埃博拉疫情持续肆虐，病人之多已远超医院负荷，感染人数仍在不断攀升，援助和疫苗也迟迟不见踪影，绝望之中，利比里亚一医生“兵行险着”，启用抗HIV药物进行治疗，不料竟获奇效。在杜伯曼堡的一家隔离中心，医生洛根让诊所内的埃博拉感染者服用了治疗艾滋病的药物拉米夫定，结果15人中13人生还，死亡率从原来的70%下降至7%。据了解，生还病人在感染后的5天内服用了拉米夫定。